Hana geht ab !!!!! News ?????? - 500 Beiträge pro Seite

[Mario12]

seid ca halben stunde explodiert Hana !!

Stehen News an ???

[StRAS]

[posting]17.437.517 von Mario12 am 03.08.05 17:00:39[/posting]Braucht keine News geben, damit Hana steigt. Sie fiel grundlos im Januar von $6 auf $2 und das wird gerade wieder wettgemacht!

[besttrader1]

Habt recht, Hanna hat fertig!

[spekulativ]

Berlin RT 3,50€

[Crush.]

NEWS von heute

von pblack im anderen Thread soeben reingestellt:



Hana Biosciences, Inc. Awarded $159,000 NIH Grant for Expanded Preclinical Development of Talotrexin in Combination Therapy


2005-08-08 07:01 ET - News Release

SOUTH SAN FRANCISCO -- (Business Wire) -- Aug. 8, 2005
Company Website: http://www.hanabiosciences.com/

Hana Biosciences, Inc. (OTCBB: HNAB), a South-San
Francisco based biopharmaceutical company focused on advancing cancer
care, was awarded a $159,000 Small Business Innovation Research (SBIR)
grant entitled " Development of PT-523 for the treatment of lung
cancer" by the National Institutes of Health (NIH). The award will
enable Hana Biosciences to expand preclinical studies of Talotrexin in
combination with other therapeutic agents as a potential
first-in-class therapeutic approach to treating various forms of
cancer.
" This grant will expand the growing body of evidence of
Talotrexin`s efficacy in combination with various novel cytotoxic and
targeted therapeutic agents in arresting tumor growth," said Mark Ahn,
PhD, President and Chief Executive Officer. " Our grant applications
continue to score highly with the NIH`s external panel of oncology
experts who are impressed with Talotrexin`s potential therapeutic
benefits, as well as with our drug development team`s ability to move
drug candidates from the laboratory to the clinic on a timely basis."

About Talotrexin (PT-523)

Talotrexin (PT-523) is a novel nonpolyglutamatable antifolate drug
being developed for a wide range of tumors including NSCLC (non-small
cell lung cancer), ALL (acute lymphocytic leukemia), cervical,
endometrial, and ovarian cancers. Compared to currently available
antifolates such as methotrexate or pemetrexed (Alimta(R); Eli Lilly)
in preclinical studies, Talotrexin enters into cells up to 10-times
more efficiently, overcomes resistance by remaining active in tumors
by not requiring polyglutamation, and binds more tightly to its
anti-tumor target DHFR which enhances efficacy. Thus, Phase I trial in
solid tumors, Ph I/II in NSCLC (non-small cell lung cancer), and Ph
I/II in ALL (acute lymphocytic leukemia) are ongoing. Ph II trials in
cervical, endometrial, ovarian cancers forthcoming.

About Hana Biosciences

Hana Biosciences, Inc. (OTCBB: HNAB) is a South San Francisco,
CA-based biopharmaceutical company that acquires, develops, and
commercializes innovative products to advance cancer care. The company
is committed to creating value by building a world-class team,
accelerating the development of lead product candidates, expanding its
pipeline by being the alliance partner of choice, and nurturing a
unique company culture. Additional information on Hana Biosciences can
be found at www.hanabiosciences.com.

This press release contains forward-looking statements that
involve risks and uncertainties that could cause Hana`s actual results
to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual outcomes
and results to differ materially from these statements. Among other
things, there can be no assurances that any of Hana`s development
efforts relating to its product candidates will be successful. Other
risks that may affect forward-looking information contained in this
press release include the possibility of being unable to obtain
regulatory approval of Hana`s product candidates, the risk that the
results of clinical trials may not support Hana`s claims, Hana`s
reliance on third party researchers to develop its product candidates
and its lack of experience in developing pharmaceutical products.
Additional risks are described in the company`s Form 8-K filed with
the Securities and Exchange Commission on August 4, 2004. Hana assumes
no obligation to update these forward-looking statements, except as
required by law.
Contacts:

Hana Biosciences, Inc.
Russell Skibsted, 650-588-6464
Fax: [phone]
[e-mail]
or
The Investor Relations Group
Christie Mazurek, 212-825-3210
Fax: [phone]
[e-mail]